Phenothrin

Summary

Phenothrin (CHEMBL1322884) is an approved small-molecule pyrethroid ester insecticide (ATC P03AC03); indicated across 1 condition including parasitic infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P03AC03 (+1 more)
• Indications: 1 condition
• Chemistry: 350.4 Da · C23H26O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1322884
Name	Phenothrin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4767
ChEBI	CHEBI:34916
ATC	P03AC03, P03AC53
Molecular formula	C23H26O3
Molecular weight	350.4
InChIKey	SBNFWQZLDJGRLK-UHFFFAOYSA-N

SMILES: CC(=CC1C(C1(C)C)C(=O)OCC2=CC(=CC=C2)OC3=CC=CC=C3)C

IUPAC name: (3-phenoxyphenyl)methyl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate

Pharmacological roles (ChEBI): pyrethroid ester insecticide.

Also known as: D-phenotrhin, Fenotrina, Full marks, Hegor antipoux, NSC-758668, Phenothrin, Phenothrine, S-2539F, Sumithrin, SID26747802, PHENOTHRIN, SID144211887

Patent coverage: 5,364 distinct patent families (18,577 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 18,528 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
parasitic infectious disease	4	MONDO:0005135	EFO:0001067

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).